JP2020511438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511438A5 JP2020511438A5 JP2019548301A JP2019548301A JP2020511438A5 JP 2020511438 A5 JP2020511438 A5 JP 2020511438A5 JP 2019548301 A JP2019548301 A JP 2019548301A JP 2019548301 A JP2019548301 A JP 2019548301A JP 2020511438 A5 JP2020511438 A5 JP 2020511438A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound according
- peaks
- compound
- xrpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 74
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 20
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 208000017701 Endocrine disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 34
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- SPQOYTHUHVSPOH-UHFFFAOYSA-N COc1cc(OC)c(CN(Cc2c3c(Nc(cc4)ccc4C(N4CCCC4)=O)cc(-c(c(F)ccc4)c4F)n2)C3=O)cc1 Chemical compound COc1cc(OC)c(CN(Cc2c3c(Nc(cc4)ccc4C(N4CCCC4)=O)cc(-c(c(F)ccc4)c4F)n2)C3=O)cc1 SPQOYTHUHVSPOH-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010066946 Craniofacial dysostosis Diseases 0.000 description 1
- 201000006526 Crouzon syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GWWOUMPOESIDNE-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)[Zn] Chemical compound FC1=C(C(=CC=C1)F)[Zn] GWWOUMPOESIDNE-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022164799A JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2024127741A JP2024153877A (ja) | 2017-03-08 | 2024-08-02 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468688P | 2017-03-08 | 2017-03-08 | |
| US62/468,688 | 2017-03-08 | ||
| PCT/US2018/021265 WO2018165240A1 (en) | 2017-03-08 | 2018-03-07 | Tyk2 inhibitors, uses, and methods for production thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164799A Division JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511438A JP2020511438A (ja) | 2020-04-16 |
| JP2020511438A5 true JP2020511438A5 (enExample) | 2021-04-15 |
| JP7160824B2 JP7160824B2 (ja) | 2022-10-25 |
Family
ID=63446346
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548301A Active JP7160824B2 (ja) | 2017-03-08 | 2018-03-07 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2022164799A Active JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2024127741A Pending JP2024153877A (ja) | 2017-03-08 | 2024-08-02 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164799A Active JP7535086B2 (ja) | 2017-03-08 | 2022-10-13 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| JP2024127741A Pending JP2024153877A (ja) | 2017-03-08 | 2024-08-02 | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10336752B2 (enExample) |
| EP (2) | EP4338802A3 (enExample) |
| JP (3) | JP7160824B2 (enExample) |
| CN (1) | CN110582501B (enExample) |
| AR (1) | AR111233A1 (enExample) |
| AU (3) | AU2018230737B2 (enExample) |
| CA (1) | CA3055209A1 (enExample) |
| IL (1) | IL269036B2 (enExample) |
| TW (3) | TWI783978B (enExample) |
| WO (1) | WO2018165240A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| DK3658557T3 (da) | 2017-07-28 | 2024-07-29 | Takeda Pharmaceuticals Co | Tyk2-inhibitorer og anvendelser deraf |
| UY38144A (es) | 2018-03-12 | 2019-10-31 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| FI3870579T3 (fi) * | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibiittoreita ja niiden käyttöjä |
| AU2020218267A1 (en) * | 2019-02-07 | 2021-09-30 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| BR112021019070A2 (pt) | 2019-03-26 | 2022-02-15 | Ventyx Biosciences Inc | Ligantes de pseudoquinase tyk2 |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| IL287665A (en) * | 2019-04-30 | 2022-07-01 | Celgene Corp | Combined treatments including apremilaste and tyk2 inhibitors |
| IL292785B2 (en) | 2019-11-08 | 2025-09-01 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| EP4404930A1 (en) * | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| AU2022378463A1 (en) | 2021-10-25 | 2024-05-09 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2023183910A1 (en) * | 2022-03-25 | 2023-09-28 | Nimbus Lakshmi, Inc. | Solid forms of tyk2 inhibitors and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4983612A (en) * | 1989-10-05 | 1991-01-08 | American Home Products Corporation | Antihypertensive benzopyran derivatives |
| DE4343923A1 (de) * | 1993-12-22 | 1995-06-29 | Basf Ag | Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses |
| CN1195755C (zh) | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3－d]嘧啶化合物 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DE60325740D1 (de) | 2002-08-14 | 2009-02-26 | Silence Therapeutics Ag | Verwendung von protein-kinase-n-beta |
| WO2004046103A2 (en) * | 2002-11-18 | 2004-06-03 | The Regents Of The University Of California | Arylpyridine compounds |
| JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| SI1644363T1 (sl) | 2003-05-30 | 2012-07-31 | Gemin X Pharmaceuticals Canada Inc | Triheterociklične spojine sestavki in postopki za zdravljenje raka |
| EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| ES2873875T3 (es) | 2004-05-13 | 2021-11-04 | Icos Corp | Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano |
| NZ555947A (en) | 2005-01-19 | 2010-11-26 | Rigel Pharmaceuticals Inc | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CN101282948A (zh) | 2005-10-07 | 2008-10-08 | 埃克塞里艾克西斯公司 | N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途 |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| PT1966202E (pt) | 2005-12-13 | 2012-01-03 | Incyte Corp | Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| DK2529622T3 (en) | 2006-09-22 | 2018-05-07 | Pharmacyclics Llc | INHIBITORS OF BRUTON-TYROSINKINASE |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| BRPI0909040B8 (pt) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | derivados de azetidina e ciclobutano, seus usos, e composição |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| RU2620376C2 (ru) * | 2010-12-22 | 2017-05-25 | Людвиг-Максимилианс-Университэт Мюнхен | Цинкорганические комплексы, способы их получения и применение |
| WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
| PL2634185T3 (pl) * | 2012-03-02 | 2016-06-30 | Sareum Ltd | Inhibitory kinazy TYK2 |
| EP2855451B1 (en) | 2012-05-24 | 2017-10-04 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
| TWI620737B (zh) | 2012-11-08 | 2018-04-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| WO2014074661A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
| WO2015089143A1 (en) | 2013-12-10 | 2015-06-18 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| CA2940666C (en) | 2014-02-28 | 2022-08-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| TWI825663B (zh) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
-
2018
- 2018-03-07 JP JP2019548301A patent/JP7160824B2/ja active Active
- 2018-03-07 CN CN201880028375.5A patent/CN110582501B/zh active Active
- 2018-03-07 CA CA3055209A patent/CA3055209A1/en active Pending
- 2018-03-07 EP EP24153142.5A patent/EP4338802A3/en active Pending
- 2018-03-07 TW TW107107562A patent/TWI783978B/zh active
- 2018-03-07 TW TW111146722A patent/TWI868528B/zh active
- 2018-03-07 EP EP18764569.2A patent/EP3592746B1/en active Active
- 2018-03-07 IL IL269036A patent/IL269036B2/en unknown
- 2018-03-07 AU AU2018230737A patent/AU2018230737B2/en active Active
- 2018-03-07 AR ARP180100523A patent/AR111233A1/es unknown
- 2018-03-07 TW TW113147070A patent/TW202515876A/zh unknown
- 2018-03-07 US US15/914,074 patent/US10336752B2/en active Active
- 2018-03-07 WO PCT/US2018/021265 patent/WO2018165240A1/en not_active Ceased
-
2019
- 2019-05-21 US US16/417,901 patent/US11040967B2/en active Active
-
2022
- 2022-10-13 JP JP2022164799A patent/JP7535086B2/ja active Active
- 2022-10-19 AU AU2022256121A patent/AU2022256121A1/en not_active Abandoned
-
2024
- 2024-08-02 JP JP2024127741A patent/JP2024153877A/ja active Pending
- 2024-08-07 AU AU2024205575A patent/AU2024205575A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511438A5 (enExample) | ||
| JP2017506675A5 (enExample) | ||
| US10479793B2 (en) | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | |
| US11919906B2 (en) | Crystal form of ACP-196 and method of treatment thereof | |
| JP2018537501A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JP2013533314A5 (enExample) | ||
| TW201630901A (zh) | 製備ａｓｋ１抑制劑之方法 | |
| JP2018505199A (ja) | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 | |
| TW201617319A (zh) | （２ｓ，３ｓ）７－氟－２－（４－氟苯基）－３－（１－甲基－１ｈ－１，２，４－三唑－５－基）－４－側氧基－１，２，３，４－四氫喹啉－５－羧酸甲酯之共形成體鹽及其製備方法 | |
| JP2015516968A5 (enExample) | ||
| WO2014174846A1 (ja) | 固形医薬組成物 | |
| WO2020170980A1 (ja) | ハロゲン化ブテン化合物の製造方法 | |
| WO2022223027A1 (zh) | Tolebrutinib晶型、无定型及其制备方法和用途 | |
| MA40480B1 (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| WO2020208592A1 (en) | Process for preparation of erdafitinib, its purification and amorphous solid dispersion | |
| US20160362391A1 (en) | Improved Process for the Preparation of Pomalidomide and its Purification | |
| CN116113633A (zh) | 一种作为可透脑的btk或her2抑制剂的化合物及其制备方法与用途 | |
| JPWO2020112937A5 (enExample) | ||
| JP6349306B2 (ja) | 錠剤 | |
| JPWO2020081508A5 (enExample) | ||
| CN111712486B (zh) | 卡利拉嗪盐酸盐的晶型及其制备方法及其用途 | |
| JPWO2022193499A5 (enExample) | ||
| US10717729B2 (en) | Thiamine-organic acid salt | |
| TWI360533B (en) | Process for the preparation of intermediates |